Logo image of RNA

AVIDITY BIOSCIENCES INC (RNA) Stock Fundamental Analysis

USA - NASDAQ:RNA - US05370A1088 - Common Stock

47 USD
+2.82 (+6.38%)
Last: 10/3/2025, 8:01:19 PM
48.25 USD
+1.25 (+2.66%)
After Hours: 10/3/2025, 8:01:19 PM
Fundamental Rating

4

Overall RNA gets a fundamental rating of 4 out of 10. We evaluated RNA against 536 industry peers in the Biotechnology industry. While RNA has a great health rating, there are worries on its profitability. While showing a medium growth rate, RNA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RNA has reported negative net income.
RNA had a negative operating cash flow in the past year.
In the past 5 years RNA always reported negative net income.
RNA had a negative operating cash flow in each of the past 5 years.
RNA Yearly Net Income VS EBIT VS OCF VS FCFRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -33.29%, RNA is in the better half of the industry, outperforming 63.62% of the companies in the same industry.
The Return On Equity of RNA (-38.21%) is better than 73.13% of its industry peers.
Industry RankSector Rank
ROA -33.29%
ROE -38.21%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
RNA Yearly ROA, ROE, ROICRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNA Yearly Profit, Operating, Gross MarginsRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNA has been increased compared to 1 year ago.
The number of shares outstanding for RNA has been increased compared to 5 years ago.
There is no outstanding debt for RNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNA Yearly Shares OutstandingRNA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RNA Yearly Total Debt VS Total AssetsRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

RNA has an Altman-Z score of 20.26. This indicates that RNA is financially healthy and has little risk of bankruptcy at the moment.
RNA has a Altman-Z score of 20.26. This is amongst the best in the industry. RNA outperforms 91.42% of its industry peers.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.26
ROIC/WACCN/A
WACC10.01%
RNA Yearly LT Debt VS Equity VS FCFRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

RNA has a Current Ratio of 9.26. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.26, RNA is in the better half of the industry, outperforming 79.10% of the companies in the same industry.
RNA has a Quick Ratio of 9.26. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 9.26, RNA is doing good in the industry, outperforming 79.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.26
Quick Ratio 9.26
RNA Yearly Current Assets VS Current LiabilitesRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for RNA have decreased strongly by -21.09% in the last year.
Looking at the last year, RNA shows a small growth in Revenue. The Revenue has grown by 1.21% in the last year.
The Revenue has been growing by 36.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.15%
Revenue 1Y (TTM)1.21%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%88.12%

3.2 Future

Based on estimates for the next years, RNA will show a very strong growth in Earnings Per Share. The EPS will grow by 23.95% on average per year.
Based on estimates for the next years, RNA will show a very strong growth in Revenue. The Revenue will grow by 170.60% on average per year.
EPS Next Y-55.42%
EPS Next 2Y-31.57%
EPS Next 3Y-5.04%
EPS Next 5Y23.95%
Revenue Next Year11.01%
Revenue Next 2Y52.23%
Revenue Next 3Y231.38%
Revenue Next 5Y170.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RNA Yearly Revenue VS EstimatesRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
RNA Yearly EPS VS EstimatesRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNA Price Earnings VS Forward Price EarningsRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNA Per share dataRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as RNA's earnings are expected to decrease with -5.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.57%
EPS Next 3Y-5.04%

More info and screens

0

5. Dividend

5.1 Amount

RNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVIDITY BIOSCIENCES INC

NASDAQ:RNA (10/3/2025, 8:01:19 PM)

After market: 48.25 +1.25 (+2.66%)

47

+2.82 (+6.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners100.03%
Inst Owner Change0%
Ins Owners0.83%
Ins Owner Change-0.14%
Market Cap6.38B
Analysts85.45
Price Target69.47 (47.81%)
Short Float %18.54%
Short Ratio6.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.42%
Min EPS beat(2)-21.39%
Max EPS beat(2)0.55%
EPS beat(4)2
Avg EPS beat(4)-2.84%
Min EPS beat(4)-21.39%
Max EPS beat(4)9.54%
EPS beat(8)4
Avg EPS beat(8)-0.44%
EPS beat(12)8
Avg EPS beat(12)3.6%
EPS beat(16)10
Avg EPS beat(16)1.14%
Revenue beat(2)1
Avg Revenue beat(2)70.43%
Min Revenue beat(2)-18.03%
Max Revenue beat(2)158.88%
Revenue beat(4)2
Avg Revenue beat(4)47.03%
Min Revenue beat(4)-45.8%
Max Revenue beat(4)158.88%
Revenue beat(8)4
Avg Revenue beat(8)21.36%
Revenue beat(12)8
Avg Revenue beat(12)17.32%
Revenue beat(16)10
Avg Revenue beat(16)11.95%
PT rev (1m)1.21%
PT rev (3m)1.86%
EPS NQ rev (1m)0.84%
EPS NQ rev (3m)-10.32%
EPS NY rev (1m)1.06%
EPS NY rev (3m)-10.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)32.09%
Revenue NY rev (1m)6.63%
Revenue NY rev (3m)53.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 594.8
P/FCF N/A
P/OCF N/A
P/B 5.35
P/tB 5.35
EV/EBITDA N/A
EPS(TTM)-3.56
EYN/A
EPS(NY)-5
Fwd EYN/A
FCF(TTM)-3.7
FCFYN/A
OCF(TTM)-3.61
OCFYN/A
SpS0.08
BVpS8.78
TBVpS8.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.29%
ROE -38.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 417.33%
Cap/Sales 118.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.26
Quick Ratio 9.26
Altman-Z 20.26
F-Score1
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.15%
EPS Next Y-55.42%
EPS Next 2Y-31.57%
EPS Next 3Y-5.04%
EPS Next 5Y23.95%
Revenue 1Y (TTM)1.21%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%88.12%
Revenue Next Year11.01%
Revenue Next 2Y52.23%
Revenue Next 3Y231.38%
Revenue Next 5Y170.6%
EBIT growth 1Y-82.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.83%
EBIT Next 3Y-1.52%
EBIT Next 5YN/A
FCF growth 1Y-190.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-188.36%
OCF growth 3YN/A
OCF growth 5YN/A